Spinnaker Biosciences
Spinnaker Biosciences is a preclinical-stage biotechnology company developing nanoporous silicon-based drug delivery platforms for ophthalmology, oncology, and nucleic acid therapeutics, founded in 2009 by UC San Diego researchers.
- Company typePrivate
- Founded2009
- HeadquartersSolana Beach, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Spinnaker Biosciences firmographics
Firmographics- Name
- Spinnaker Biosciences
- Legal name
- Spinnaker Biosciences, Inc.
- Website
- https://spinnakerbiosciences.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Spinnaker Biosciences is a preclinical-stage biotechnology company developing nanoporous silicon-based drug delivery platforms for ophthalmology, oncology, and nucleic acid therapeutics, founded in 2009 by UC San Diego researchers.
- Ownership category
- akta.pro rank
Spinnaker Biosciences industry classification
Industry- Product category
- Drug Delivery Technology
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in Nanotechnology (541713)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Crystallization, Particle Engineering & Micronization Services (HLAGAHAJ)
- akta.pro secondary industries
- RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD), Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods) (HLAAACAC)
Keywords
Where Spinnaker Biosciences is headquartered
LocationHeadquarters
- HQ city
- Solana Beach
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Spinnaker Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Spinnaker Biosciences product offering
Product offeringCore offering
Spinnaker Biosciences develops a drug delivery platform based on nanoporous silicon, porous silicon oxide, and porous silicon/polymer composite materials. The particles feature precisely tuned nano-pores that act as a protective cage for therapeutic payloads and provide controlled, sustained drug release. The platform supports applications in ophthalmology (e.g., ranibizumab-loaded silicon oxide for wet AMD), oncology (EPR-effect mediated chemotherapy delivery), and gene/nucleic acid therapy via fusogenic liposome-coated nanoparticles.
Product overview
Spinnaker Biosciences is a biotech company developing a platform of porous silicon-based drug delivery technologies. The core product is the Nanoporous Silicon Particles Platform, which encompasses multiple formulations including Fusogenic Liposome-Coated Nanoparticles for gene/RNA delivery, Ranibizumab Loaded Silicon Oxide Particles for ophthalmology, Surface Functionalized Porous Silicon Particles, and Oncology Applications. These materials serve as controlled release drug delivery vehicles that protect therapeutic payloads while enabling sustained, tunable drug release with biocompatible and biodegradable properties.
Differentiator
Problem solved
Functional benefit
Products and services
- Nanoporous Silicon Particles Platform A drug delivery platform using porous silicon, porous silicon oxide, and porous silicon/polymer composite materials with tunable nano-pores designed for controlled and sustained drug release. The particles are biocompatible, biodegradable, and injectable, serving as a protective cage for therapeutic payloads and accommodating a wide range of drugs and release rates. Targeted at pharmaceutical partners developing ophthalmic, oncologic, and other therapeutic products.
- Fusogenic Liposome-Coated Nanoparticles Silicon nanoparticles formulated with fusogenic liposomes that load and protect high quantities of nucleic acids (siRNA, mRNA, DNA) without cytotoxic polymer stabilizers. The coating enables delivery to the cytosol by bypassing endosomal uptake and degradation, intended for gene therapy and nucleic acid delivery applications.
- Ranibizumab Loaded Silicon Oxide Particles Silicon oxide particles loaded with ranibizumab for sustained ocular delivery in the treatment of wet age-related macular degeneration (AMD), providing continuous drug release for over four months and reducing injection frequency compared to standard dosing every 6–8 weeks.
- Surface Functionalized Porous Silicon Particles Porous silicon particles with selective, differential functionalization of interior and exterior surfaces that improves loading capacity and dispersibility while allowing control of drug release kinetics for additional applications beyond the core ophthalmology and oncology programs.
- Oncology Drug Delivery System Nanoparticle-based drug delivery exploiting abnormal tumor vascular architecture and the Enhanced Permeability and Retention (EPR) effect to selectively deliver chemotherapeutics to tumor tissues, with preclinical data showing nanoparticle concentrations in tumors several-fold higher than plasma levels, reducing systemic toxicity.
Quantifiable outcome
- Animal safety studies demonstrated non-toxic formulation with no observable tissue damage in vivo
- +2 more outcomes
Companies that use Spinnaker Biosciences
Customer profileSegments3 records
Ideal customer profiles1 record
Spinnaker Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Spinnaker Biosciences partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights3 records
Spinnaker Biosciences competitors and assessment
Company assessmentDirect peers
- EyePoint Pharmaceuticals: Specialty ophthalmology company developing sustained-release drug delivery for retinal diseases including wet AMD. Direct competitor to Spinnaker's ocular program (ranibizumab-loaded silicon oxide particles) and most directly comparable given shared indication and sustained-release focus.
- Ocular Therapeutix: Ophthalmology company developing sustained-release intravitreal and intracameral drug delivery platforms. Highly comparable to Spinnaker's ophthalmology program given shared therapeutic area and extended-release positioning.
- Durect Corporation: Specialty pharma developing sustained-release drug delivery systems using bioerodible polymers. Directly comparable to Spinnaker's porous silicon sustained-release technology, including efforts targeting ophthalmology and other indications.
- pSivida (now part of EyePoint): Historical developer of bioerodible sustained-release ocular implants and porous silicon-based delivery technology. Closely related platform heritage to Spinnaker's nanoporous silicon approach and a relevant historical reference point.
- Graybug Vision (acquired by Catalent): Developed sustained-release drug delivery technologies for wet AMD and other retinal diseases. Direct competitor to Spinnaker's ophthalmology sustained-release program with overlapping therapeutic and technical positioning.
Emerging players
- Selecta Biosciences: Developer of nanoparticle-based immunomodulatory and antigen-specific tolerogenic drug delivery platforms. Comparable to Spinnaker in nanoparticle engineering for biologic delivery, though focused on immunology applications.
- BIND Therapeutics (acquired by Pfizer): Pre-acquisition, developed targeted polymeric nanoparticles for controlled-release chemotherapeutic delivery. Directly relevant precedent for nanoparticle-based oncology drug delivery, comparable to Spinnaker's EPR-mediated oncology program.
- Cerulean Pharma (acquired by Daré Bioscience): Developed nanoparticle-drug conjugates (nanopharmaceuticals) for oncology. Comparable mechanism to Spinnaker's tumor-targeted nanoparticle delivery via EPR and polymeric nanoparticle engineering.
- enGene (now part of KALA BIO): Develops nucleotide-based drug delivery platforms using bio-nanoparticle technology for ocular and other indications. Comparable to Spinnaker's nucleic acid delivery platform, particularly the fusogenic liposome-coated nanoparticles.
Broad incumbents
- Arcturus Therapeutics: Clinical-stage company with LNP-based delivery platforms for mRNA, siRNA, and gene editing therapeutics. Comparable to Spinnaker's fusogenic liposome-coated nanoparticle nucleic acid delivery approach, though at significantly later stage and broader scale.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks6 records
Key highlights6 records
Customer concentration
Spinnaker Biosciences social profiles
Digital presenceSpinnaker Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Spinnaker Biosciences leadership team
Management profileNumber of profiles
Profiles3 records
Spinnaker Biosciences funding detail
Funding detailFunding overview
Funding rounds3 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Spinnaker Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Spinnaker Biosciences
What does Spinnaker Biosciences do?
Spinnaker Biosciences develops a drug delivery platform based on nanoporous silicon, porous silicon oxide, and porous silicon/polymer composite materials. The particles feature precisely tuned nano-pores that act as a protective cage for therapeutic payloads and provide controlled, sustained drug release. The platform supports applications in ophthalmology (e.g., ranibizumab-loaded silicon oxide for wet AMD), oncology (EPR-effect mediated chemotherapy delivery), and gene/nucleic acid therapy via fusogenic liposome-coated nanoparticles.
Is Spinnaker Biosciences a public or private company?
Spinnaker Biosciences is a private company. It is classified as unknown and is currently operating.
When was Spinnaker Biosciences founded?
Spinnaker Biosciences was founded in 2009. It employs 1 to 10 people.
Where is Spinnaker Biosciences based?
Spinnaker Biosciences is headquartered in Solana Beach, United States, in the North America region.
Who are Spinnaker Biosciences's main competitors?
Direct peers on record are EyePoint Pharmaceuticals, Ocular Therapeutix, Durect Corporation, pSivida (now part of EyePoint) and Graybug Vision (acquired by Catalent). Emerging players are Selecta Biosciences, BIND Therapeutics (acquired by Pfizer), Cerulean Pharma (acquired by Daré Bioscience) and enGene (now part of KALA BIO). Arcturus Therapeutics is listed as a broad incumbent.
Does Spinnaker Biosciences have an API?
No public API is recorded for Spinnaker Biosciences.
What industry is Spinnaker Biosciences in?
Spinnaker Biosciences's product category is Drug Delivery Technology. Its primary akta.pro industry code is HLAGAHAJ, Crystallization, Particle Engineering & Micronization Services, with a secondary code of HLAAADAD, RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes). Its NAICS code is 325414 and its SIC code is 2836.